Tonix Pharmaceuticals (TNXP) to Help Raise Fibromyalgia Awareness through Partnership with America Chronic Pain Association
Development-stage specialty pharmaceutical company Tonix Pharmaceuticals Holding Corp. announced it has become a corporate partner of the American Chronic Pain Association (ACPA) as part of that organization’s efforts to raise awareness about fibromyalgia, a syndrome increasingly identified in people who suffer chronic pain and believed to affect around 5 million people in the United States. Currently, Tonix is developing TNX-102 SL, its lead clinical candidate for treating fibromyalgia and post-traumatic stress disorder. Tonix recently announced the initiation of the BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) clinical trial – the first of two anticipated pivotal trials for TNX-102…